| Autor: |
Morgan K; Merck Serono Ltd., Feltham, UK, an affiliate of Merck KGaA., Van Dommelen P; The Netherlands Organization for Applied Scientific Research TNO, Leiden, The Netherlands., Batista AR; Merck Serono Ltd., Feltham, UK, an affiliate of Merck KGaA., Koledova E; Merck Healthcare KGaA, Darmstadt, Germany. |
| Jazyk: |
angličtina |
| Zdroj: |
Studies in health technology and informatics [Stud Health Technol Inform] 2022 May 25; Vol. 294, pp. 817-818. |
| DOI: |
10.3233/SHTI220595 |
| Abstrakt: |
We explored whether a multi-component approach - using a digital health device, the easypod™ auto-injector, the 'MySupport' patient support programme (PSP) and a Patient Activation Measure® (PAM®) - could improve adherence in patients receiving recombinant human growth hormone (r-hGH). A 13-item PAM was used to assess caregiver self-reported knowledge, resulting in two PAM scores for 88 patients at four UK hospitals after an average of 5.6 months. Most patients improved their PAM score by ≥1 level (43%) or maintained it (>-1 and <1; 21%). In parallel, 74% of patients maintained (-5 to +5%) or improved (≥5%) their adherence. Further studies are required to evaluate a multi-component approach to adherence in a larger population and for a longer duration. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
